KRYS
Price
$141.52
Change
+$2.51 (+1.81%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
4.02B
40 days until earnings call
TRVI
Price
$5.97
Change
+$0.27 (+4.74%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
694M
36 days until earnings call
Interact to see
Advertisement

KRYS vs TRVI

Header iconKRYS vs TRVI Comparison
Open Charts KRYS vs TRVIBanner chart's image
Krystal Biotech
Price$141.52
Change+$2.51 (+1.81%)
Volume$1.25K
Capitalization4.02B
Trevi Therapeutics
Price$5.97
Change+$0.27 (+4.74%)
Volume$109.68K
Capitalization694M
KRYS vs TRVI Comparison Chart in %
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. TRVI commentary
Jul 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and TRVI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 03, 2025
Stock price -- (KRYS: $139.01 vs. TRVI: $5.70)
Brand notoriety: KRYS and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 73% vs. TRVI: 129%
Market capitalization -- KRYS: $4.02B vs. TRVI: $694M
KRYS [@Biotechnology] is valued at $4.02B. TRVI’s [@Biotechnology] market capitalization is $694M. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 0 FA rating(s) are green whileTRVI’s FA Score has 0 green FA rating(s).

  • KRYS’s FA Score: 0 green, 5 red.
  • TRVI’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than TRVI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 5 TA indicator(s) are bullish while TRVI’s TA Score has 3 bullish TA indicator(s).

  • KRYS’s TA Score: 5 bullish, 3 bearish.
  • TRVI’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than TRVI.

Price Growth

KRYS (@Biotechnology) experienced а -3.24% price change this week, while TRVI (@Biotechnology) price change was -1.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.46%. For the same industry, the average monthly price growth was +33.64%, and the average quarterly price growth was +2.14%.

Reported Earning Dates

KRYS is expected to report earnings on Aug 11, 2025.

TRVI is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+1.46% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.02B) has a higher market cap than TRVI($694M). TRVI YTD gains are higher at: 38.350 vs. KRYS (-11.266). KRYS has higher annual earnings (EBITDA): 140M vs. TRVI (-47.23M). KRYS has more cash in the bank: 617M vs. TRVI (103M). TRVI has less debt than KRYS: TRVI (957K) vs KRYS (9.66M). KRYS has higher revenues than TRVI: KRYS (333M) vs TRVI (0).
KRYSTRVIKRYS / TRVI
Capitalization4.02B694M579%
EBITDA140M-47.23M-296%
Gain YTD-11.26638.350-29%
P/E Ratio33.34N/A-
Revenue333M0-
Total Cash617M103M599%
Total Debt9.66M957K1,010%
FUNDAMENTALS RATINGS
KRYS vs TRVI: Fundamental Ratings
KRYS
TRVI
OUTLOOK RATING
1..100
2158
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
4180
SMR RATING
1..100
5797
PRICE GROWTH RATING
1..100
6249
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRVI's Valuation (55) in the Pharmaceuticals Major industry is in the same range as KRYS (71). This means that TRVI’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (41) in the Pharmaceuticals Major industry is somewhat better than the same rating for TRVI (80). This means that KRYS’s stock grew somewhat faster than TRVI’s over the last 12 months.

KRYS's SMR Rating (57) in the Pharmaceuticals Major industry is somewhat better than the same rating for TRVI (97). This means that KRYS’s stock grew somewhat faster than TRVI’s over the last 12 months.

TRVI's Price Growth Rating (49) in the Pharmaceuticals Major industry is in the same range as KRYS (62). This means that TRVI’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as TRVI (100). This means that KRYS’s stock grew similarly to TRVI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSTRVI
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
77%
Bullish Trend 27 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TRVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VSOYX44.02N/A
N/A
Victory Sycamore Small Company Opp Y
PXINX12.27N/A
N/A
Impax International Sust Econ Inv
PWGIX25.36N/A
N/A
Impax US Sustainable Economy Instl
VSFAX23.66N/A
N/A
Federated Hermes Clover Small Value A
VAKSX11.16N/A
N/A
Virtus KAR Small-Mid Cap Growth A

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with ACLX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+1.13%
ACLX - KRYS
55%
Loosely correlated
-1.76%
IDYA - KRYS
54%
Loosely correlated
+0.48%
CGON - KRYS
54%
Loosely correlated
+1.35%
XNCR - KRYS
54%
Loosely correlated
+2.67%
CRNX - KRYS
54%
Loosely correlated
-1.15%
More

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with PTGX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then PTGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
+4.20%
PTGX - TRVI
42%
Loosely correlated
-9.16%
BIESF - TRVI
42%
Loosely correlated
N/A
GOSS - TRVI
33%
Poorly correlated
+1.63%
MLYS - TRVI
31%
Poorly correlated
+1.26%
QURE - TRVI
30%
Poorly correlated
+0.36%
More